Anti-SARS-CoV-1, Spike RBD (Clone COV1-90) – Purified No Carrier Protein
Anti-SARS-CoV-1, Spike RBD (Clone COV1-90) – Purified No Carrier Protein
Product No.: S1004
- -
- -
Product No.S1004 Clone COV1-90 Target SARS-CoV-1 ⋅ Spike RBD Formats AvailableView All Product Type Recombinant Monoclonal Antibody Alternate Names SARS, S2 protein, Spike glycoprotein 2 Isotype Human IgG1κ Applications B , N |
- -
- -
Antibody DetailsProduct DetailsReactive Species SARS-CoV-1 Expression Host HEK-293 Cells Immunogen Sequenced from PBMCs from a donor who had recovered from a naturally-occurring SARS infection. Product Concentration ≥1.0 mg/ml Purity ≥90% monomer by analytical SEC and SDS-Page Formulation This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? B, N Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity COV1-90 targets the receptor-binding domain (RBD) of the SARS-CoV-1 prefusion
spike protein (S2), located on the viral surface. Background SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. COV1-90 is a monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-1 spike protein and does not cross-react with the SARS-CoV-2 spike protein. This antibody effectively blocks the ACE2 receptor, preventing the virus from binding to and entering host cells. Additionally, COV1-90 functions as a neutralizer, further inhibiting viral entry and replication. The dual function of blocking ACE2 and neutralizing the virus makes COV1-90 a potent candidate for therapeutic use, offering a comprehensive approach to preventing and treating COVID-19. Its specificity for the RBD ensures targeted action against the virus, making it a crucial component in antibody therapies. Antigen Distribution Anti-SARS-CoV-1 recognizes antigens on infected cells, including
respiratory epithelial cells. NCBI Gene Bank ID UniProt.org Research Area Category C Pathogens . Infectious Disease . Viral . IVD Raw Material References & Citations1.Mann R, Perisetti A, Gajendran M, Gandhi Z, Umapathy C, Goyal H. Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. Front Med (Lausanne). 2020;7:581521. 2.Rat P, Olivier E, Dutot M. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential. Eur Rev Med Pharmacol Sci. 2020;24(14):7880-7885. |
Formats Available
- -
- -
Prod No. | Description |
---|---|
S1004 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.